Technical Analysis for GOVX - GeoVax Labs, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | -1.23% | |
Gapped Up | Strength | -1.23% | |
20 DMA Support | Bullish | -0.62% | |
Wide Bands | Range Expansion | -0.62% | |
Pocket Pivot | Bullish Swing Setup | -2.42% | |
Wide Bands | Range Expansion | -2.42% | |
Crossed Above 20 DMA | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% | |
Earnings Movers | Other | 0.00% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 1 hour ago |
Up 3% | about 1 hour ago |
Up 2% | about 1 hour ago |
Down 1% | about 3 hours ago |
Up 1% | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/14/2024
GeoVax Labs, Inc. Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Infectious Diseases Immunotherapies Vaccines Allergy Hepatitis B Department Of Defense Viruses HIV Immunodeficiency U.S. Department Of Defense Virus Malaria Fever Virology Ebola Zika Chronic Hepatitis Scripps Vaccinia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.5365 |
52 Week Low | 1.38 |
Average Volume | 31,347 |
200-Day Moving Average | 5.39 |
50-Day Moving Average | 1.85 |
20-Day Moving Average | 1.55 |
10-Day Moving Average | 1.51 |
Average True Range | 0.17 |
RSI (14) | 47.92 |
ADX | 18.06 |
+DI | 18.43 |
-DI | 14.49 |
Chandelier Exit (Long, 3 ATRs) | 1.46 |
Chandelier Exit (Short, 3 ATRs) | 1.89 |
Upper Bollinger Bands | 1.77 |
Lower Bollinger Band | 1.33 |
Percent B (%b) | 0.68 |
BandWidth | 28.45 |
MACD Line | -0.09 |
MACD Signal Line | -0.14 |
MACD Histogram | 0.0441 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.77 | ||||
Resistance 3 (R3) | 1.78 | 1.74 | 1.75 | ||
Resistance 2 (R2) | 1.74 | 1.70 | 1.73 | 1.74 | |
Resistance 1 (R1) | 1.68 | 1.68 | 1.66 | 1.68 | 1.73 |
Pivot Point | 1.64 | 1.64 | 1.63 | 1.64 | 1.64 |
Support 1 (S1) | 1.59 | 1.61 | 1.57 | 1.58 | 1.53 |
Support 2 (S2) | 1.55 | 1.58 | 1.54 | 1.52 | |
Support 3 (S3) | 1.49 | 1.55 | 1.51 | ||
Support 4 (S4) | 1.49 |